Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We have been discussing how R&D biotech's are valued on results and the promise of a treatment. Here is a good example.
Believe it or not, an analyst stating the following in a report lead to the 1000% increase. You cannot determine a biotech or pharmaceutical company's valuation like you do other public companies...
"Ritu Baral, an analyst at Cowen & Co., said the drug, AQX-1125, now has a better probability of success for bladder pain and may have some value for eczema."
Now imagine what can happen if Dr Von Hoff or even an analyst expresses that type of luke warm confidence in treatments for all abdominal cancers, malignant ascites. It is important to understand the potential of what you own...
http://www.bloomberg.com/news/articles/2015-08-10/aquinox-soars-as-company-moves-ahead-with-pain-and-eczema-drug
Great DD, Rudy... Very nice to see this plan coming together. And we have the best of the best helping us get there...
PharmaCyte Biotech Hires Industry-Leading Firm to Assist With Investigational New Drug Application
September 25, 2015
http://ir.pharmacytebiotech.com/press-releases/detail/55/pharmacyte-biotech-hires-industry-leading-firm-to-assist
"Nuvilex's COO, Dr. Gerry Crabtree, says his company also plans to apply to have the FDA "Fast Track" its unique live-cell encapsulation-based treatment for advanced, inoperable pancreatic cancer that consists of tiny pin-head-sized capsules containing live drug-activating cells combined with the long known and widely used cancer drug, ifosfamide, once the biotech enters its future late-stage clinical trials. And, there is no reason to believe that Nuvilex wouldn't also be granted the FDA designation if it can continue to confirm the data the company has seen in its two independent Phase II clinical trials."
9/11/2013...
http://www.marketwired.com/press-release/nuvilex-eyes-fda-fast-track-after-abraxane-approved-for-pancreatic-cancer-otcqb-nvlx-1829444.htm
Thanks for those reminders Rudy. Fast Track could literally be around the corner...
Yes and they are an overseas company. We could possibly be the first US based biotech to use cannabanoids to treat cancer.
PharmaCyte Biotech Advances Cannabinoid Research With Schedule 1 License
June 15, 2015 09:25 ET | Source: PharmaCyte Biotech, Inc.
SILVER SPRING, Md., June 15, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its research partner, the University of Northern Colorado (UNC), successfully obtained a Schedule 1 license from the U.S. Drug Enforcement Agency (DEA) enabling the company to continue development of tumor-targeted treatments for serious and deadly cancers by utilizing cannabinoid prodrugs in combination with Cell-in-a-Box® live cell encapsulation.
Although marijuana (Cannabis) is legal in the state of Colorado, use of Cannabis for research purposes at an institution that has federal grants such as UNC is not permitted by the DEA without a Schedule 1 license. The source for the plant material is regulated by DEA, and this material must be obtained through the National Institute for Drug Abuse. With the DEA license, it is now possible for researchers at UNC to obtain both the plant material and specific cannabinoid reference standards needed to conduct the research.
“As we were applying for the Schedule 1 license, ‘model’ compounds, or cannabinoid look-alikes, were utilized to develop research protocols and screen various biological systems,” noted PharmaCyte Biotech’s Principal Investigator and UNC Professor Richard M. Hyslop, Ph.D. “With the license in-hand, we are beginning experiments using the cannabinoids to reexamine the biological systems for activity as well as explore additional systems suitable for use in combination with the Cell-in-a-Box® platform.”
“We are exceedingly pleased with the work that has been accomplished to date at UNC and congratulate Dr. Hyslop and his colleagues at UNC on successfully obtaining the Schedule 1 license,” said Kenneth L. Waggoner, PharmaCyte Biotech’s Chief Executive Officer. “Now that we have the ability to isolate potentially useful substances from the Cannabis plant itself, we can continue development of Cannabis-derived prodrugs and engineered human cell lines for use with the versatile Cell-in-a-Box® platform. These types of natural or ‘green’ approaches to fighting disease offer a potentially huge upside for patients who suffer from all kinds of maladies, not the least of which is brain cancer.”
Obtaining a DEA Schedule 1 license is a rigorous process. In addition to outlining a legitimate and worthwhile line of scientific investigation in a formal application, the process at UNC included inspection of the laboratory facilities, review of UNC’s plans for record-keeping and confirmation of facility security. Records accounting for all types and quantities of Cannabis ordered, when and how used and means of disposal must be maintained and available for DEA officials during site visits. The license is renewable annually.
- See more at: http://globenewswire.com/news-release/2015/06/15/744618/0/en/PharmaCyte-Biotech-Advances-Cannabinoid-Research-With-Schedule-1-License.html#sthash.46fwbNUY.dpuf
http://globenewswire.com/news-release/2015/06/15/744618/0/en/PharmaCyte-Biotech-Advances-Cannabinoid-Research-With-Schedule-1-License.html
Book value would apply for them. They are not a biotech. Check out the article I attached. The link is even better because not everything could be copied and pasted.
It's the potential value of the treatment of a biotech that is the valuation. The more validation for the treatment, the greater the value. Getting IND and Fast Track approval will create greater value here. But the real value comes during human trials as milestones are achieved. And then of course when this gets to market.
Our pps is low because we are in R&D with no revenue an pending trials. But having NDAs means potential partners or buyers to either help us get to market or buy us out and do it themselves.
When looking at this bio, we are talking oncology, including treatments for pain and malignant ascites, and diabetes, for now.
For the time being, PharmaCyte is comfortably financed through a $50 million at- the-market facility. But with the prospect of large trials looming down the road, the company also is assessing the interest of big pharmas, and many have signed nondisclosure agreements.
“We’ve been approached by a number of people who want to get involved,” Waggoner said. “They’ve recognized that our treatment is very different from any approach that’s out there.”
https://attachment.fbsbx.com/file_download.php?id=430488960477321&eid=ASs8H56RBw6-I04BvjrtHMr3v8M-3UWMSnSPZOIaieKlKWtbed5oEkt2qFFeKlCqf8o&ext=1443226132&hash=ASv3E8kbAa6fz_tQ
Good to hear from you Jimmy Joe. We are building a biotech powerhouse here! :)
I found "nothing"
Book value does not apply to a biotech, especially one in R&D...
Using DCF In Biotech Valuation
By Ben McClure
It can be tricky to put a price tag on biotechnology companies that offer little more than the promise of success in the future. Just because someone in the lab cries "Eureka!," that doesn't necessarily mean that a cure has been found. In the biotech sector, it can take many years to determine whether all the effort will translate into returns for a company. However, while valuation may appear to be more guesswork than science, there is a generally accepted approach to valuing biotech companies that are years away from payoff. In this article, we explain this valuation approach, which relies on discounted cash flow (DCF) analysis, and take you through the process step by step.
Portfolio Valuation Approach
Think of a biotech company as a collection of one or more experimental drugs, each representing a potential market opportunity. The idea is to treat each promising drug as a mini-company within a portfolio. Using DCF analysis, you can determine what someone would be willing to pay for that drug portfolio.
In other words, you determine the forecasted free cash flow of each drug to establish its separate present value. Then, you add together the net present value of each drug, along with any cash in the bank, and come up with a fair value for what the whole company is worth today.
A biotech company can have dozens or even hundreds of drugs in its developmental pipeline. However, that does not mean you should include them all in your valuation. Generally speaking, you should only include those drugs that are already in one of the three clinical trial stages. (For more information, visit the U.S. Food and Drug Administration's website.) As an investment, a drug that is in the discovery or pre-clinical stage is a very risky proposition, with less than a 1% chance of getting to market (according to an industry report published in 2003 by the Pharmaceutical Research and Manufacturers of America). Therefore, drugs in the pre-clinical stage are usually assigned zero value by public market investors.
Forecasting Sales Revenue
Forecasting the sales revenue from each of a biotech company's drugs is probably the most important estimate you can make about future cash flows, but it can also be the most difficult. The key is to determine what expected peak sales would be if - and this is a big "if" - a drug successfully makes it all the way through clinical trials. Normally, you will forecast sales for the first 10 years of the drug's life.
Market Potential
You need to start by making assumptions about the drug's market potential. Look at information provided by the company and market research reports to determine the size of the patient group that will use the drug. Analysts typically focus on market potential in the industrialized countries, where people will pay the market price for drugs.
When making assumptions about a drug's potential market penetration, you have to use your own best judgment. If there is a competitive drug market, with limited advantage offered by the new drug in terms of increased effectiveness or reduced side effects, the drug will probably not win substantial market share in its product category. You may assume that it will capture 10% of that total market, or even less. On the other hand, if no other drug addresses the same needs, you might assume the drug will enjoy market penetration of 50% or more.
Estimated Price Tag
Once you have established a sales market size, you need to come up with an estimated sales price. Of course, putting a price tag on a drug that addresses an unmet need will involve some guesswork. But for a drug that will compete with existing products, you should look at the price of the competition. For instance, pharmaceutical giant Roche's recently introduced HIV-inhibitor drug, Fuzeon, costs just over $20,000 per year. Multiplying that price by the estimated number of patients gives you estimated annual peak sales.
The biotech company won't necessarily receive all of this sales revenue. Many biotech firms - especially the smaller ones with little capital - do not have sales and marketing divisions capable of selling high volumes of drugs. They often license promising drugs to bigger pharmaceutical companies, which help pay for development and become responsible for making sales. In return, the biotech firm normally receives royalty on future sales. According to an article written by Medius Associates ("Royalty Rates: Current Issues and Trends," October 2001), the royalty rate for drugs currently in Phase I of clinical trials is normally a percentage in the single digits. As these firms move along the development pipeline, royalty rates get higher.
In Figure 1, we break down an estimate of the peak annual sales revenues for a hypothetical biotech drug in a competitive market with a potential market size of 1 million patients, an estimated sales price of $20,000 per year and a royalty rate of 10%.
Potential Market Size 1 million patients
Market Penetration Rate -Competition High 10%
Estimated Market Size 100,000 patients
Sales Price $20,000 per year
Peak Sales $2 billion per year
Royalty Rate 10%
Peak Annual Sales Revenues $200 million
Figure 1 - Calculating drug sales revenue
Drug patents usually last about 10 years. In our hypothetical example, we assume that for the first five years after commercial launch, sales revenues from the drug will increase until they hit their peak. Thereafter, peak sales continue for the remaining life of the patent.
Figure 2 - Hypothetical estimate of sales revenue for the chosen forecast period of 10 years
Estimating Costs
When forecasting future cash flows for a drug, you need to consider the costs of discovery and bringing the drug to market.
For starters, there are operating costs associated with the discovery phase, including efforts to discover the drug's molecular basis, followed by lab and animal tests. Then there is the cost of running clinical trials. This includes the cost of manufacturing the drug, recruiting, treating and caring for the participants, and other administrative expenses. Expenses increase in each development phase. All the while, there is ongoing capital investment in items such as laboratory equipment and facilities. Taxation and working capital costs also need to be factored in. Investors should expect operating and capital costs to represent no less than 30% of the drug's royalty-based sales.
By deducting the drug's operating costs, taxes, net investment and working capital requirements from its sales revenues, you arrive at the amount of free cash flow generated by the drug if it becomes commercial.
Accounting for Risk
Our free cash flow forecast assumes that the drug makes it all the way through clinical trials and is approved by regulators. But we know this doesn't always happen. So, depending on the drug's stage of development, we must apply a probability factor to account for its probability of success.
As the drug moves through the development process, the risk decreases with each major milestone. The Pharmaceutical Research and Manufacturers of America reported in 2003 that drugs entering Phase I clinical trials have a 15% probability of becoming a marketable product. For those in Phase II, the odds of success rise to 30%, and for Phase III, they climb to 60%. Once clinical trials are complete and the drug enters the final FDA approval phase, it has a 90% chance of success. These improvements in the odds of success translate directly into stock value.
By multiplying the drug's estimated free cash flow by the stage-appropriate probability of success, you get a forecast of free cash flows that accounts for development risk.
The next step is to discount the drug's expected 10-year free cash flows to determine what they are worth today. Because you have already factored in risk by applying the clinical trial probability of success, you do not need to include development risk in the discount rate. You can rely on normal means of calculating the discount rate, such as the weighted average cost of capital (WACC) approach, to come up with the drug's final discounted cash flow valuation.
What's the Firm Worth?
Finally, you want to calculate the total value of the biotech firm. Once you have gone through all the steps outlined above to calculate the discounted cash flow for each of the biotech firm's drugs, you simply need to add them all up to get a total value for the firm's drug portfolio.
DCF Value Drug A + DCF Value Drug B + DCF Drug C … … = Total Firm Value
The Bottom Line
As you can see, valuing early-stage biotech companies is not entirely a black art. Intelligent investors can come up with solid stock valuation estimates if they are familiar with DCF analysis and are equipped with a basic understanding of the industry and how major developmental milestones can impact the value of a biotech firm
http://www.investopedia.com/articles/stocks/06/biotechvaluation.asp#ixzz3mQ3vhXjP
$PMCB Nice Close and a good weekend to all!
We're right at that second resistance point. Good post... And happy Friday. Great and significant news today!
http://finance.yahoo.com/news/pharmacyte-biotech-hires-industry-leading-132500552.html
True dat!
Great shared DD, Bio...
"We look forward to using our expertise in drug development, quality and compliance to help them (PMCB) bring their novel encapsulated live cell product to market.”
Steven Chamow
Chamow & Associates
Thanks for the post Bassett. I appreciate those who are usually quiet coming on to show support. This is hardly over. I feel bad for those who seem to have given up.
It can certainly be difficult to hang in when things look grim but I truly believe they are looking at the wrong things.... The game is hardly over...
Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
Warren Buffett
Great article, Pete, and very true. I am even impressed by the level of intelligence of the retail investors attracted to this stock. They know how to do their DD and though it may be rough at these levels, many are hanging tough.
Not only are they smart but they have heart.
I still believe it is, yes. I don't believe this pps is reflective of the value of this technology at all. I do think the lengthy process to get to major milestones is discouraging for some. But this is a R&D biotech. It will take time to get us there. I am not shaken and I am thankful that I have not been. I really want to see the plans Dr Von Hoff has for this technology.
The plan has been laid out and a lot of work is going on behind the scenes. Don't forget we have NDAs and interested parties watching our progress.
It's difficult to watch the pps drop while some seem truly excited about it and celebrating a further drop. Playing with your mind...
"You have to stand for something or you will fall for anything."
The game is not over. Not time for celebration or defeat, IMO....
GLTA
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117149159
http://globenewswire.com/news-release/2015/09/15/768385/0/en/PharmaCyte-Biotech-Discusses-Major-Milestones-Ahead-of-Phase-2b-Clinical-Trial-in-Pancreatic-Cancer.html
Thanks Brian. I am looking forward to trials and changing lives as well with this technology. I have been a shareholder since 2/2014 and I am impressed with the progress we've made towards that goal.
Good luck to you as well and thanks for your post.
http://www.biomedreports.com/20150518222991/qaa-with-pharmacyte-ceo-kenneth-l-waggoner-on-pmcbs-new-direction.html
Well they sure aren't making daily efforts to say either way. They don't seem to need to try and affect the pps either.
And they are long, the point being made, and they are not bitter about the past 10 years. So, not everyone who has been here for a long time feels they have been ripped off...
I just don't get having so much animosity toward a company. It makes no sense to me. Whatever, I will just move on. Thanks for the discussion...
I think a lot of people flip, I believe some are long so that would not surprise me, but I have never heard them try and talk the price down. And whenever we hear from them, they say positive things about the company. And they don't gripe and complain, completely different approach.
PMCB... Another great post... :)
That is not true. We have heard and seen plenty of doctors speak to CiaB technology and many more have written about it.
I know many who have been here just as long as you have and they are long and believers, esusan and efood are just a couple. They don't share your same sentiment at all.
So, I still think there is more to this story.
In fact, I know this video has been shown before but with a comment like "you talk about the doctors but we never hear from them." , it's time to manage by facts...
http://www.pharmacytebiotech.com/pharmacyte-biotech-corporate-video-june-1-2015/
Fabulous post!
If that were true, aren't there better ways to seek justice? Or is it that some have a perception of an injustice that is not warranted?
I look and see a great technology, world renowned doctors and a very strategic plan to get us to human trials, FDA approval and market. I also see regular filings with complete transparency as well.
Now, if someone has a gripe to bear for previous losses, the potential for gains is huge here.
And, you have said before that you hold a core position, why would you do that if you don't believe there is potential to have some realized gains here?
I think there is way too much interest in seeing this pps drop. Why? Supposedly, naked shorts are minimal but who roots for a team to lose unless they have something to gain?
That is a really great article. Dr Crabtree did a superior job of explaining exactly what is this treatment and how it works...
That makes total sense to me, Bio.
Of course I would say the same thing. Note that nothing material must change with the company. If they are still on track, I am still a believer. My shares are in very strong hands... :)
They don't need to change that. They just need to be part of the 10% that do make it.
Great questions MEM.... I can take some guesses on the answers to those questions but I don't really know. I do know Dr Rabe and Dr Salmons are on the PMCB website which makes me think everything is under one roof now but it's just a guess.
Thanks and I don't invest more than I can afford so not much pain here, especially since I am in no rush to realized gains...
I don't have to imagine it, I did it and would do it again. A difference of 30 cents a share will be meaningless in the end.
Don't get me wrong, I would own 3-4x as many shares as I do now for the same amount of money today but the point is, I am a shareholder at any price because I believe this technology is capable of revolutionizing medical treatments for cancer and diabetes.
I believe so much I am willing to take the risk. I totally understand anyone who would prefer not to risk their money on a R&D bio.. Good thing there are so many other options...
So much talk about valuation of a biotech I thought it important to hear from a professional. Biotechs which have drug treatments in the pipeline are not valued the same way as other companies. I just feel like there are so many who really don't understand how to invest in bios... So here is a little something to consider for those who want to better understand how all this works with a bio still in R&D...
Using DCF In Biotech Valuation
By Ben McClure
It can be tricky to put a price tag on biotechnology companies that offer little more than the promise of success in the future. Just because someone in the lab cries "Eureka!," that doesn't necessarily mean that a cure has been found. In the biotech sector, it can take many years to determine whether all the effort will translate into returns for a company. However, while valuation may appear to be more guesswork than science, there is a generally accepted approach to valuing biotech companies that are years away from payoff. In this article, we explain this valuation approach, which relies on discounted cash flow (DCF) analysis, and take you through the process step by step.
Portfolio Valuation Approach
Think of a biotech company as a collection of one or more experimental drugs, each representing a potential market opportunity. The idea is to treat each promising drug as a mini-company within a portfolio. Using DCF analysis, you can determine what someone would be willing to pay for that drug portfolio.
In other words, you determine the forecasted free cash flow of each drug to establish its separate present value. Then, you add together the net present value of each drug, along with any cash in the bank, and come up with a fair value for what the whole company is worth today.
A biotech company can have dozens or even hundreds of drugs in its developmental pipeline. However, that does not mean you should include them all in your valuation. Generally speaking, you should only include those drugs that are already in one of the three clinical trial stages. (For more information, visit the U.S. Food and Drug Administration's website.) As an investment, a drug that is in the discovery or pre-clinical stage is a very risky proposition, with less than a 1% chance of getting to market (according to an industry report published in 2003 by the Pharmaceutical Research and Manufacturers of America). Therefore, drugs in the pre-clinical stage are usually assigned zero value by public market investors.
Forecasting Sales Revenue
Forecasting the sales revenue from each of a biotech company's drugs is probably the most important estimate you can make about future cash flows, but it can also be the most difficult. The key is to determine what expected peak sales would be if - and this is a big "if" - a drug successfully makes it all the way through clinical trials. Normally, you will forecast sales for the first 10 years of the drug's life.
Market Potential
You need to start by making assumptions about the drug's market potential. Look at information provided by the company and market research reports to determine the size of the patient group that will use the drug. Analysts typically focus on market potential in the industrialized countries, where people will pay the market price for drugs.
When making assumptions about a drug's potential market penetration, you have to use your own best judgment. If there is a competitive drug market, with limited advantage offered by the new drug in terms of increased effectiveness or reduced side effects, the drug will probably not win substantial market share in its product category. You may assume that it will capture 10% of that total market, or even less. On the other hand, if no other drug addresses the same needs, you might assume the drug will enjoy market penetration of 50% or more.
Estimated Price Tag
Once you have established a sales market size, you need to come up with an estimated sales price. Of course, putting a price tag on a drug that addresses an unmet need will involve some guesswork. But for a drug that will compete with existing products, you should look at the price of the competition. For instance, pharmaceutical giant Roche's recently introduced HIV-inhibitor drug, Fuzeon, costs just over $20,000 per year. Multiplying that price by the estimated number of patients gives you estimated annual peak sales.
The biotech company won't necessarily receive all of this sales revenue. Many biotech firms - especially the smaller ones with little capital - do not have sales and marketing divisions capable of selling high volumes of drugs. They often license promising drugs to bigger pharmaceutical companies, which help pay for development and become responsible for making sales. In return, the biotech firm normally receives royalty on future sales. According to an article written by Medius Associates ("Royalty Rates: Current Issues and Trends," October 2001), the royalty rate for drugs currently in Phase I of clinical trials is normally a percentage in the single digits. As these firms move along the development pipeline, royalty rates get higher.
In Figure 1, we break down an estimate of the peak annual sales revenues for a hypothetical biotech drug in a competitive market with a potential market size of 1 million patients, an estimated sales price of $20,000 per year and a royalty rate of 10%.
Potential Market Size 1 million patients
Market Penetration Rate -Competition High 10%
Estimated Market Size 100,000 patients
Sales Price $20,000 per year
Peak Sales $2 billion per year
Royalty Rate 10%
Peak Annual Sales Revenues $200 million
Figure 1 - Calculating drug sales revenue
Drug patents usually last about 10 years. In our hypothetical example, we assume that for the first five years after commercial launch, sales revenues from the drug will increase until they hit their peak. Thereafter, peak sales continue for the remaining life of the patent.
Figure 2 - Hypothetical estimate of sales revenue for the chosen forecast period of 10 years
Estimating Costs
When forecasting future cash flows for a drug, you need to consider the costs of discovery and bringing the drug to market.
For starters, there are operating costs associated with the discovery phase, including efforts to discover the drug's molecular basis, followed by lab and animal tests. Then there is the cost of running clinical trials. This includes the cost of manufacturing the drug, recruiting, treating and caring for the participants, and other administrative expenses. Expenses increase in each development phase. All the while, there is ongoing capital investment in items such as laboratory equipment and facilities. Taxation and working capital costs also need to be factored in. Investors should expect operating and capital costs to represent no less than 30% of the drug's royalty-based sales.
By deducting the drug's operating costs, taxes, net investment and working capital requirements from its sales revenues, you arrive at the amount of free cash flow generated by the drug if it becomes commercial.
Accounting for Risk
Our free cash flow forecast assumes that the drug makes it all the way through clinical trials and is approved by regulators. But we know this doesn't always happen. So, depending on the drug's stage of development, we must apply a probability factor to account for its probability of success.
As the drug moves through the development process, the risk decreases with each major milestone. The Pharmaceutical Research and Manufacturers of America reported in 2003 that drugs entering Phase I clinical trials have a 15% probability of becoming a marketable product. For those in Phase II, the odds of success rise to 30%, and for Phase III, they climb to 60%. Once clinical trials are complete and the drug enters the final FDA approval phase, it has a 90% chance of success. These improvements in the odds of success translate directly into stock value.
By multiplying the drug's estimated free cash flow by the stage-appropriate probability of success, you get a forecast of free cash flows that accounts for development risk.
The next step is to discount the drug's expected 10-year free cash flows to determine what they are worth today. Because you have already factored in risk by applying the clinical trial probability of success, you do not need to include development risk in the discount rate. You can rely on normal means of calculating the discount rate, such as the weighted average cost of capital (WACC) approach, to come up with the drug's final discounted cash flow valuation.
What's the Firm Worth?
Finally, you want to calculate the total value of the biotech firm. Once you have gone through all the steps outlined above to calculate the discounted cash flow for each of the biotech firm's drugs, you simply need to add them all up to get a total value for the firm's drug portfolio.
DCF Value Drug A + DCF Value Drug B + DCF Drug C … … = Total Firm Value
The Bottom Line
As you can see, valuing early-stage biotech companies is not entirely a black art. Intelligent investors can come up with solid stock valuation estimates if they are familiar with DCF analysis and are equipped with a basic understanding of the industry and how major developmental milestones can impact the value of a biotech firm
http://www.investopedia.com/articles/stocks/06/biotechvaluation.asp#ixzz3mQ3vhXjP
Thanks, Bio. You are very kind...
I am not willing to take the chance of this getting out of reach for me.
At the same time, if the price drops that low and if nothing material has changed with the company, I will be buying as well. :)
A realist, sure do appreciate your honesty but remember that we are still in R&D. Once we start getting recent human trial results, then it will make sense to pay attention to the market's reaction via the PPS. Right now we have to pay for those trials with no revenue. :)
Also, currently we only have preclinical trial results which we heard were good from the company but nothing is published yet.
And, the past results are over 10 years old. We do know that CiaB has been improved in that time to hold more prodrugs which should show improved results.
We do have FDA ODD and plans in place to get us to new trials with some of the best pancreatic cancer specialists in the world.
So, standing on the sidelines makes sense if you don't really trust that everything will fall in place, however, the price could jump significantly and fast once particular milestones are met.
I see you watching this one closely and wish you the best in your timing. :)
Not only that Bio but we will also be working with patients to improve their quality of life by reducing pain and treating malignant ascites.
I would definitely like to see us in human trials and treating patients successfully.
We are on track to do this and I certainly wish everyone who is working toward this goal the best and thank them for all their efforts as well...
Great post Bio...
All new for PharmaCyte...
Yes, shorting over 40% everyday this week...
Nice to close in the green on the last day of the week. :)
DD would have shown you the mice studies were not complete over a year ago...
And can you provide any evidence that these doctors have a record of pretending to do studies for a company for pay? Can you provide evidence of any respected doctor doing studies for a company just to get paid? That is so counterintuitive... Doctors who have dedicated their lives to research and practice to save the lives of victims of cancer have suddenly decided to help a small company with no revenue pull of a scam that could put all of them in jail...?
PharmaCyte Biotech Begins Second Follow-Up Study on Ascites
SILVER SPRING, Md., July 23, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology,
Cell-in-a-Box®, announced today that its follow-up study on ascites began this week. That study is being conducted by Translational Drug Development (TD2) to determine the effectiveness of PharmaCyte Biotech’s pancreatic cancer treatment on the rate of accumulation of malignant ascites fluid in patients with pancreatic cancer and other abdominal tumors.
This study was designed by Dr. Daniel D. Von Hoff of TD2 and key members of PharmaCyte Biotech’s scientific team. This is the third study on ascites being conducted by TD2. In this study, as in the previous two studies, mice with ovarian cancer are being used in a model that grows rapidly and produces significant amounts of malignant ascites fluid. Nine groups of mice will be used in this study, with 10 mice in each group. One group will be used as a vehicle control, and in the other eight groups, four different doses of ifosfamide will be used.
The goal of the study is to “fine tune” PharmaCyte’s treatment to slow down the accumulation of ascites that will serve best in the clinical setting. The Company’s
treatment uses low doses of the prodrug ifosfamide together with Cell-in-a-Box® capsules that are filled with live cells capable of converting ifosfamide into its cancer-killing form.
In the initial “proof of principle” study, four groups of mice were used. The mice in Group 1 served as a control group. Group 2 was made up of mice treated with PharmaCyte Biotech’s pancreatic cancer treatment. Group 3’s mice were treated with cisplatin, a chemotherapy drug often used to treat ovarian cancer, and the mice in Group 4 were treated with a combination of PharmaCyte Biotech’s pancreatic cancer treatment and cisplatin. Because of the positive results from this pilot study, the first follow-up study using 12 groups of mice was done to begin to define parameters that will be needed in defining the most appropriate treatment regimen to be used in a clinical trial.
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented, “After careful consideration and analysis of data from the first two studies on ascites, we believe that this follow-up study is appropriate. In conjunction with the results of the first follow-up study, the parameters that will be necessary for designing a Phase 1 clinical trial should be more clearly defined when this study is completed. All of these studies are extremely important, not only for PharmaCyte Biotech but also for the many patients who endure malignant ascites – a serious symptom without a cure or even a way to slow down its accumulation.”
The accumulation of ascites fluid is problematic for patients with an abdominal cancer, such as pancreatic, liver, ovarian, uterine and colon cancers. This is because it is very painful and can cause breathing and other serious problems. Once it gets to a certain stage, it must be removed on a regular basis. This procedure in itself is very uncomfortable for patients as well as costly. PharmaCyte Biotech expects that the Cell-in-
a-Box® plus ifosfamide combination will ultimately prove to be effective in slowing the accumulation of malignant ascites fluid and thus reduce the number of withdrawals of the fluid that patients with abdominal cancers must endure over a given period of time.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary
cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®” This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed.
PharmaCyte Biotech’s treatment for pancreatic cancer involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or “cancer-killing” form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one third the normal dose to eliminate adverse side effects. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of the drug takes place at or near the tumor. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of Cell-in-a-
Box® technology in optimizing the anticancer effectiveness ofCannabis, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.
In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line, which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done
using the Cell-in-a-Box® technology.
I'd like to see you answer that same question. Why repeat the same thing over and over, for what 10 years now?
And believe me, no one gives merit to anyone who makes claims they cannot back with some DD.
And, I know quite a few people who believe in this company, including the renowned doctors mentioned in the article, Von Hoff, Hidalgo and Lohr...
And, there are lots of folks who appreciate DD so they can make an educated decision about their investment choices. So, I will continue to share all the DD I see fit to help others see what these great doctors see as well...
Have a good weekend...
http://www.otcmarkets.com/stock/PMCB/news/PharmaCyte-Biotech-s-Improved-Technology-Attracting-World-Class-Oncologists?id=110900&b=y